Next Article in Journal
Editorial for the Topical Collection “SARS-CoV-2 Infection and COVID-19 Disease”
Previous Article in Journal
New Frontier on Antimicrobial Therapy: Long-Acting Lipoglycopeptides
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Adema et al. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703

by
Jennifer L. Adema
1,*,
Aileen Ahiskali
2,
Madiha Fida
3,
Krutika Mediwala Hornback
4,
Ryan W. Stevens
5 and
Christina G. Rivera
5,*
1
Department of Pharmacy, East Carolina University Health, Greenville, NC 27834, USA
2
Department of Pharmacy, Hennepin Healthcare, Minneapolis, MN 55415, USA
3
Division of Public Health, Infectious Diseases and Occupational Medicine, Mayo Clinic, Rochester, MN 55902, USA
4
Department of Pharmacy, Medical University of South Carolina (MUSC) Health, Charleston, SC 29425, USA
5
Department of Pharmacy, Mayo Clinic, Rochester, MN 55902, USA
*
Authors to whom correspondence should be addressed.
Pathogens 2024, 13(3), 190; https://doi.org/10.3390/pathogens13030190
Submission received: 2 February 2024 / Accepted: 2 February 2024 / Published: 21 February 2024
Text Correction
There was an error in the original publication [1]. A typo in the twelfth sentence of the first paragraph of Section 2.3, “Cefazolin vs. ASPs”, was noted by the authors. It should read “p = 0.034” instead of “p = 0.34”.
The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication has also been updated.

Reference

  1. Adema, J.L.; Ahiskali, A.; Fida, M.; Mediwala Hornback, K.; Stevens, R.W.; Rivera, C.G. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Adema, J.L.; Ahiskali, A.; Fida, M.; Mediwala Hornback, K.; Stevens, R.W.; Rivera, C.G. Correction: Adema et al. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703. Pathogens 2024, 13, 190. https://doi.org/10.3390/pathogens13030190

AMA Style

Adema JL, Ahiskali A, Fida M, Mediwala Hornback K, Stevens RW, Rivera CG. Correction: Adema et al. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703. Pathogens. 2024; 13(3):190. https://doi.org/10.3390/pathogens13030190

Chicago/Turabian Style

Adema, Jennifer L., Aileen Ahiskali, Madiha Fida, Krutika Mediwala Hornback, Ryan W. Stevens, and Christina G. Rivera. 2024. "Correction: Adema et al. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703" Pathogens 13, no. 3: 190. https://doi.org/10.3390/pathogens13030190

APA Style

Adema, J. L., Ahiskali, A., Fida, M., Mediwala Hornback, K., Stevens, R. W., & Rivera, C. G. (2024). Correction: Adema et al. Heartbreaking Decisions: The Dogma and Uncertainties of Antimicrobial Therapy in Infective Endocarditis. Pathogens 2023, 12, 703. Pathogens, 13(3), 190. https://doi.org/10.3390/pathogens13030190

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop